Cholecystokinin-A receptor antagonists: therapies for gastrointestinal disorders

Bibliography

• ALBUS M: Cholecystokinin. Prog. Neuropsychopharmacol Biol. PFchiat. (1988) 12:S5–S21.
   PubMed Web of Science ®Google Scholar
• CRAWLEY JN: Cholecystokinin-dopamine interactions. Trends Pharmacol Sci. (1991) 12:232–235.
   PubMed Web of Science ®Google Scholar
• CRAWLEY JN, VANDERHAEGHEN J-J: Neuronal Cholecystok-inin. Ann. NY Acad. ScL (1985) 448:1–697.
   PubMed Web of Science ®Google Scholar
• HOKFELT T, CORTES R, SCHALLING M eta].: Distribution patterns of CCK and CCK mRNA in some neuronal and nonneuronal tissues. Neuropeptides (1991) 19:31–4.
   Google Scholar
• MORLEY JE: Minireview: the ascent of cholecystokinin (CCK) from gut to brain. Life ScL (1982) 30:479–493.
   PubMed Web of Science ®Google Scholar
• MORAN TH, MCHUGH PR: Gastric mechanisms in CCK satiety. In: Multiple Cholecystokinin Receptors in the CNS Dourish CT, Couper SJ, Iversen SD, Iversen LL (Eds.), Oxford University Press, Oxford, UK (1992):183–205.
   Google Scholar
• MUTT V: Cholecystokinin: Mob, structure and function. In: GI Hormones. Glass GB (Ed.), Raven Press, New York (1980169–203.
   Google Scholar
• SMITH GP, GIBBS J: The development and proof of the CCK hypothesis of satiety. In: Multiple Cholecystokinin Receptors in the CNS Dourish CT, Couper SJ, Iverson SD, Iverson LL (Eds.), Oxford University Press, Oxford, UK (1992) 183–205.
   Google Scholar
• WALSH JH: GI hormones: gastrin and cholecystokinin. In: Physiology of the GI Tract; Johnson LR, Alpers DH, Christensen J, Jacobson ED, Walsh JH (Eds.), Raven Press, New York (1994) 3–31, 49–67.
   Google Scholar
• CRAWLEY JN, CORWIN RL: Biological actions of cholecystokinin. Peptides (1994) 15 (4):731–755. Comprehensive review of CCK literature.
   Google Scholar
• DOURISH CT, HILL DR: Classification and function of CCK receptors. Trends Pharmacol Sci. (1987) 8:207–208.
   Web of Science ®Google Scholar
• JENSEN RT, HUANG SC, SCHRENK T, WANK SA, GARDENER JD: Cholecystokinin receptor antagonists: ability to distinguish various classes of cholecystokinin receptors. In: GI Endocrinology Receptors and Post-receptor Mechanisms. Thompson JC (Ed.), Academic Press, San Diego (1990):95–111.
   Google Scholar
• RASMUSSEN K: Therapeutic potential of cholecystokinin-B antagonists. Exp. Opin. Invest. Drugs (1995) 4 (4) :313–322.
   Google Scholar
• D'AMATO M, MAKOVEC F, ROVATI LC: Potential clinical applications of CCKA receptor antagonists in gastroenterology. Drug News & Perspect. (1994) 7(4:87–95.
   Google Scholar
• SILVENTE-POIROT S, DUFRESNE M, VAYSSE N, FOURMY D: The peripheral cholecystokinin receptors. Eur. J. Biochem. (1993) 215:513–529.
   PubMedGoogle Scholar
• WANK SA: Cholecystokinin receptors. Am. J. Physiol.
   Google Scholar
• ••Detailed and comprehensive review on the molecular biology of CCK receptors.
   Google Scholar
• WILLIAMS JA, BLEVINS GT: Cholecystokinin and regulation of pancreatic acinar cell function. Physiol Rev. (1993) 73:701–723.
   PubMed Web of Science ®Google Scholar
• WOODRUFF GN, HUGHES J: Cholecystokinin antagonists. Ann. Rev. Pharmacol Toxicol (1991) 31:469–501
   PubMed Web of Science ®Google Scholar
• Cholecystokinin Antagonists in Gastroenterology: Basic and
   Google Scholar
• ••Clinical Status. Adler G, Beglinger C (Eds.), Springer-Verlag,Berlin-Heidelberg (1991). Multi-authored book devoted to the development and charac-terisation of CCKA antagonists covering basic and clinical biochem-istry, physiology and pharmacology.
   Google Scholar
• REEVE R, EYSSELEIN V, SALOMON TE, GO VLW:
   Google Scholar
• •• Cholecystokinin. Ann. NY Acad. Sci. (1994) 713:1-467. The book contains the papers presented at the latest multidiscipli-nary conference on CCK covering all aspects of CCK biology.
   Google Scholar
• IVY AC, OLDBERG E: A hormone mechanism for gall-bladder contraction and evacuation. Am. J. Physiol. (1928) 86:599–613.
   Google Scholar
• HARPER AA, RAPER HS: Pancreozymin, a stimulant of the secre don of pancreatic enzymes in extracts of the small intestine. Physiol (fond.) (1943) 102:115–125.
   PubMedGoogle Scholar
• SANKARAN H, GOLDFINE ID, DEVENEY CW, WONG KY, WILLIAMS JA: Binding of cholecystokinin to high affinity receptors on isolated rat pancreatic acini. j Biol. Chem. (1980) 255:1849–1853.
   PubMed Web of Science ®Google Scholar
• HAY SE, BEINFELD MC, JENSEN RT, GOODWIN FK, PAUL SM: Demonstration of a putative receptor site for cholecystokinin in rat brain. Neuropeptides (1980) 1:53–62.
   Web of Science ®Google Scholar
• INNIS RB, SNYDER SH: Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl. Acad. Sci. USA (1980) 77:6917–6921.
   PubMed Web of Science ®Google Scholar
• MAKOVEC F, BANI M, CHISTÉ R et al: Differentiation of central and peripheral cholecystokinin-antagonistic activity. Arzneim. Forsch. (1986) 36:98–102.
   PubMed Web of Science ®Google Scholar
• MORAN TH, ROBINSON PH, GOLDBRICH MS: Two brain cholecystokinin receptors: implications for behavioural actions. Brain Res. (1986) 362:175–179.
   PubMed Web of Science ®Google Scholar
• SO LL AAH, AMIRAN DA, THOMAS LP, REEDY TJ, ELASHOFF JD: Gastrin receptors on isolated canine parietal cells. Clin. Invest. (1984) 73:1434–1447.
   Google Scholar
• SONG ID, BROWN RN, WILIME RN et al: The human gastrin/cholecystokinin type B receptor gene: alterna-tive splice donor site in exon 4 generates two variant mRNAs. Proc. Natl. Acad. ScL USA (1993) 90:9085–9086.
   PubMed Web of Science ®Google Scholar
• ULRICH CD, FERBER I, HOLICKY E eta].: Molecular clon-ing and functional expre ssion of the human gallbladder cholecystokinin A receptor. Biochem. Biophys. Res. Com-mun. (1993) 193:204–211.
   Google Scholar
• PISEGNA JR, DE-WEERTH A, HUPPI K, WANK SA: Molecu-lar cloning of the human br ain and gast ric cholecystok-inin receptor: structure, functional expression and chromosomal localisation. Biochem. Biophys. Res. Com-mun. (1992) 189:296–303.
   PubMed Web of Science ®Google Scholar
• BEIBORN M, LEE YM, MCBRIDE EW, QUINN SM, KOPIN AS: A single amino acid of the cholecystokinin-B/gastrin receptors determines specificity for the non-peptide antagonists. Nature (1993) 362:348–350.
   PubMed Web of Science ®Google Scholar
• BEINFELD MC: Cholecystokinin in the central nervous system: a mini review. Neuropeptides (1983) 3:411–419.
   PubMed Web of Science ®Google Scholar
• NAKATA H, MATSUI T, ITO M eta]: Cloning and charac-terisation of gastrin receptor from ECL carcinoidtumor of Mastomys natalensis. Biochem. Biophys. Res. Comm 1117. (1992) 187:1151–1157.
   PubMed Web of Science ®Google Scholar
• GRIDER JR, MAKHLOUF GM: Distinct receptors for cholecystokinin and gastrin on muscle cells of stomach and gallbladder. Am. J. Physiol. (1990) 259(22):G184–G190.
   PubMed Web of Science ®Google Scholar
• HARRO J, VASAR E, BRADWEJN J: CCK in animal and human research on anxiety. Trends Pharmacol Sci. (1993) 14:244–249.
   PubMed Web of Science ®Google Scholar
• HUGHES J, BODEN P, COSTALL B eta].: Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA (1990) 87:6728–6732.
   Google Scholar
• SINGH L, FIELD MJ, HUGES J et al.: The behavioural properties of CI-988, a selective cholecystokinin-B re-ceptor antagonist. Br. J. Pharmacol. (1991) 104:239–245.
   PubMed Web of Science ®Google Scholar
• MAKOVEC F, D'AMATO M: CCKB/gastrin receptor an-tagonists as potential drugs for peptic ulcer therapy. Drug Disc. Today (1997) 2:283–293.
   Web of Science ®Google Scholar
• LOTTI VJ, CHANG RSL: A new and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur. j Pharmacol (1989) 162:273–80.
   PubMed Web of Science ®Google Scholar
• MAKOVEC F, PERIS W, REVEL L eta]: Structure-a nt iga str inactivity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives. J. Med. Chem. (1992) 35:28–38.
   PubMed Web of Science ®Google Scholar
• PEIKIN SR, COSTENBADER CL, GARDNER JD: Actions of derivatives of cyclic nucleotides on dispersed acini from guinea-pig pancreas: discovery of a competitive antagonist of the action of cholecystokinin. J. Biol. Chem. (1989) 254:5321–5327.
   Google Scholar
• SPANARKFL M, MARTINEZ J, BRIET C, JENSEN RT, GARD-NER JD: Cholecystokinin-27-32-amide. A new class of cholecystokinin receptor antagonists. J. Biol. Chem. (1983) 258:6746–6749.
   Google Scholar
• STRAK HA, SHARP CM, STULIFF VE eta].: CCK-JMV-180: a peptide that distinguishes high-affinity cholecystok-inin receptors from low-affinity cholecystokinin recep-tors. Biochim. Biophys. Acta (1989) 1010:145–150.
   Google Scholar
• CHANG RSL, LOTTI VJ, MONAGHAN RL eta].: A potent nonpeptide cholecystokinin antagonist selective for peripheral tissue isolated from Aspergillus alliaceus. Science (1985) 230:177–179.
   Google Scholar
• LAM YKT, BOGEN D, CHANG RS eta].: Novel and potentgastric and brain cholecystokinin antagonists from Streptomyces olivaceus. Taxonomy, fermentation, iso-lation, chemical conversions, and physico-chemical and biochemical properties.' Antibiot (1991) 44:613–634.
   Google Scholar
• OHTSUKA T, KUDOH T, SHIMMA N eta]: Tetronothiodin,a novel cholecystokinin type-B receptor antagonist produced by Streptomyces sp. J. Antibiot (1991) 45:140–143.
   Web of Science ®Google Scholar
• CHANG RSL, LOTTI VJ, CHENG TB, KURKEL KA: Charac-terisation of the binding of [311]-(±)-L-364,718: a new potent, non peptide cholecystokinin antagonist radioli-gand selective for peripheral receptors. Mol. Pharmacol (1986) 30:212–217.
   PubMed Web of Science ®Google Scholar
• LOTTI VJ, CHANG RSL: A new and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur. J. Pharmacol (1989) 162:273–80.
   PubMed Web of Science ®Google Scholar
• ITO H, SOGABE H, NAKARAI T eta].: Pharmacological profile of FK480, a novel cholecystokinin type-A recep-tor antagonist: comparison to Loxiglumide. j Pharma-col. Exp. 7her. (1994) 268:571.
   Google Scholar
• FAT EL S, SMITH AJ, FLETCHER AE eta].: Biological prop-erties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo. Mol Pharmacol (1994) 46:943–948.
   Google Scholar
• SAITA Y, YAZAWA H, HONMA Y eta].: Characterizationof YM022: its CCK-B/gastrin receptor binding profile and antagonism to CCK-8-induced Cd+ mobilization. Mol Pharmacol (1994) 269:249–254.
   Google Scholar
• HULL RAD, SHANKLEY NP, HARPER EA, GERSKOWITCHVP, BLACK JW: 2-Naphthalenesulphonyl L-aspartyl-(2-phenethyDamide (2-NAP) -a selective cholecystokinin CCKA-receptor antagonist. Br. J. Pharmacol (1993) 108:734–740.
   PubMed Web of Science ®Google Scholar
• AKIYAMA T. TACHIBANA I, HIROHATA Y eta].: Pharma-cological profile of TP-680, a new cholecystikinint, receptor antagonist. Br. J. Pharmacol (1996) 117:1558–1564.
   Google Scholar
• ROVATI LC, BANI M, MAKOVEC F, REVEL L, SETNIKAR I: Lorglurnide and loxiglumide: two potent and specific antagonists of peripheral CCK. In: Gastrin and Cholecystokinin. JP Bali, J Martinez (Eds.), Elsevier, Amster-dam (1987):45–46.
   Google Scholar
• SETNIKAR I, BANI M, CEREDA R et al.: Pharmacological characterisation of a new potent and specific non-polypeptidic cholecystokinin antagonist. Arz eneim-Forsch. (1987) 37:703–707.
   PubMed Web of Science ®Google Scholar
• KERVIN JF: Further developments in cholecystokinin antagonist research. Drugs Future (1991) 16:1111–1119.
   Google Scholar
• BERTRAND P, BOHME GA, DURIEUX C et al.: Pharma-cological properties of ureido-acetamides, new potent and selective non-peptide CCK-B/gastrin receptor an-tagonists. Eur. j Pharmacol. (1994) 262:233–245.
   PubMed Web of Science ®Google Scholar
• LOWE JA, HAGEMAN DL, DROZDA SE eta].: 5-Pheny1-3-ureidobenzazepin-2-ones as cholecystokinin-B recep-tor antagonists." Med. Chem. (1994) 37:3789–3811.
   Google Scholar
• GULLY D, FREHEL D, MARCY C eta].: Peripheral biologi-cal activity of SR 27987: a new potent non-peptide antagonist of CCK-A receptors. Eur. J. Pharmacol (1993) 232:13–19.
   Google Scholar
• TANIGUCHO H, YAZAKI N, ENDO T, NAGASAKI M: Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro. Eur. j Pharmacol (1996) 304:147–154.
   PubMed Web of Science ®Google Scholar
• DENT J, DODDS WJ, FRIEDMAN RH et al: Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects.' Clin. Invest. (1980) 65:256-259. Comprehensive review on the mechanism of GERD.
   Google Scholar
• MITTAL K, HOLLOWAY RH, PANAGINI R, BLACKSHAW LA,DENT J: Transient lower esophageal sphincter relaxation. Gastroenterology (1995) 109:601–610.
   PubMed Web of Science ®Google Scholar
• LIDDLE RA, GOLDFINE ID, ROSEN MS, TAPLITZ RA, WIL-LIAMS JA: Cholecystokinin bioactivity in human plasma: molecular forms, responses to feeding, and relationship to gallbladder contraction. J. Clin. Invest. (1985) 75:1144–1152.
   PubMed Web of Science ®Google Scholar
• RESIN H, STERN DH, STURDEVANT RAL, ISENBERG JI:Effect of the C-terminal octapeptide of cholecystokinin on lower esophageal sphincter pressure in man. Gas-troenterology (1973) 64:946–949.
   PubMed Web of Science ®Google Scholar
• LEDERBOER M, MASCLEE AAM, BATSTRA MR et al: Effect of cholecystokinin on lower oesophageal sphincter pressure and transient lower oesophageal sphincter relaxations in humans. Gut (1995) 36:39–44.
   PubMed Web of Science ®Google Scholar
• ZERBIB F, BRUELY DES VARANNES S, BENTOUIMOU N etal.: Simultaneous post-prandial assessment of lower esophageal sphincter tone, proximal gastric tone and plasma cholecystokinin in normal man. Gastroenterol-ogy (1995) 108:A714.
   Google Scholar
• KATSCHINSKI M, SCHIRRA J, KOPPELBERG T et al.: Role of CCK as a physiological regulator of esophageal motility in man. Hell. J. Gasüventerol (1992) 5:158. Abstract 631.
   Google Scholar
• KATSCHINSKI M, SCHIRRA J, KOPPELBERG T et al.: Effect of CCK-A receptor blockade on esophageal motility. Eur. J. Gastroenterol. Hepatol. (1994) 6:983–986.
   Web of Science ®Google Scholar
• BOULANT J, MATHIEUS S, D'AMATO M et al.: Cholecystok-inin in transient lower oesophageal sphincter relaxa-tion due to gastric distension in humans. Gut (1997) 40:575–581.
   Google Scholar
• BOECKXSTAENS GE, FAKHRY N, D'AMATO M et al: Cholecystokinin-A receptors are involved in the trigger-ing of transient LES relaxations by gastric distension. Gastroenterology (1997) 112:A701.
   Web of Science ®Google Scholar
• TRUDGILL N, D'AMATO M, RILEY S: Effects of loxiglumide on lower oesophageal sphincter fiinction following a fat meal in healthy volunteers. Gastroenterology (1996) 110:A771.
   Web of Science ®Google Scholar
• ZERBIB F, BRULEY DES VARANNES S, D'AMATO M, SCAR-PIGNATO C, GALMICHE JP: Effect of the CCK-A receptor antagonist loxiglumide on gastric tone and transient lower esophageal sphincter relaxations in humans. Gastroenterology (1997) 112:A857.
   Web of Science ®Google Scholar
• TRUDGILL N, D'AMATO M, RILEY S: Loxiglumide inhibits post-prandial transient lower oesophageal sphincter relaxations in patients with gastro-oesophageal reflux disease. Gastroenterology (1997) 112:A315.
   PubMed Web of Science ®Google Scholar
• FAKHRY N, D'AMATO M, HIRSCH D et al: Loxiglumide inhibits meal-induced transient LES rlaxations in obese patients. Gastroenterology (1997) 112:A730.
   Web of Science ®Google Scholar
• POPE CE: Acid reflux disorders. New Engl. J. Med. (1994)331:656–660.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM KM, HOROWITZ M, RIDDELL PS et al.: Relations among autonomic nerve dysfunction oeso-phageal motility and gastric emptying in gastro-oesophageal reflux disease. Gut (1991) 32:1436–1440.
   PubMed Web of Science ®Google Scholar
• SCARPIGNATO C, VARGA G, CORRADI C: Effect of CCK and its antagonists on gastric emptying. J. Physic)]. (Paris) (1993) 87:291-301. Detailed review on the role of CCK in gastric emptying.
   Google Scholar
• DENT J: Roles of gastric acid and pH in the pathogenesis of gastro-oesophageal reflux disease. Scand. j Gastroen-terol. (1994) 29\(Suppl. 200:55–61.
   Google Scholar
• COLLEN MJ, JOHNSON DA, SHERIDAN MJ: Basal acid output and gastric acid hypersecretion in gastro-oeso-phageal reflux disease. Correlation with ranitidine therapy. Dig. Dis. Sci. (1994) 39:410–417.
   PubMed Web of Science ®Google Scholar
• TYTGAT GNJ, JANSSENS J, REYNOLDS JC, WIENBECK M:Update on the pathophysiology and management of gastro-oesophageal reflux disease: the role of prokinetic therapy. Eur. J. Gastroenterol Hepatol (1996) 8:603–611.
   PubMed Web of Science ®Google Scholar
• HILDEBRAND P, BEGLINGER C, GYR K et al: Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary response in man. J. Clin. Invest. (1990) 85:640–646.
   PubMed Web of Science ®Google Scholar
• ORLANDO RC: Pathophysiology of gastroesophageal reflux. Oesophageal epithelial resistance. In: The Oesoph-agus. Castell DO (Ed.), Little Brown, New York (1992):463–478.
   Google Scholar
• SAGAIE-SHIRAZI S, DENBESTEN L, ZIKE WL: Effect of bile salts on the ionic permeability of the oesophageal mucosa and their role in the production of es ophagitis. Gastroenterology (1975) 68:728–733.
   PubMed Web of Science ®Google Scholar
• SCARPIGNATO C: Cholecystokinin antagonists and motilides: pharmacology and potential in the treatment of gastroesophageal reflux disease and other digestive motor disorders. Front Gastrointest Res. (1992) 20:90–128.
   Google Scholar
• BEGLINGER C: Effect of cholecystokinin on gastrin motility in humans. Ann. NY Acad. Sci. (1994) 713:219–225.
   PubMed Web of Science ®Google Scholar
• ANIKA MS: Effects of cholecystokinin and caerulein on gastric emptying. Eur. j Pharmacol (1982) 85:195–199.
   PubMed Web of Science ®Google Scholar
• CHEY WY, HITANANT S, HENDRICKS J, LORBER SH: Effect of secretion and cholecystokinin on gastric emptying and gastric secretion in man. Gastroenterology (1970) 58:820–827.
   PubMed Web of Science ®Google Scholar
• DEBAS HT, FARROQ O, GROSSMAN MI: Inhibition of gastric emptying is a physiological action of cholecystokinin. Gastroenterology (1975) 68:1211–1217.
   PubMed Web of Science ®Google Scholar
• VALENZUELA JE, DEFILIPPI C: Inhibition of gastric emptying in humans by secretin, the octapeptide of cholecystokinin, andintraduodenal fat. Gastroenterology (1981) 81:898–902.
   PubMed Web of Science ®Google Scholar
• YAMAGISHI T, DEBAS HT: Cholecystokinin inhibits gastric emptying by acting on both proximal stomach and pylorus. Am. J. Physiol. (1978) 234:E375–E378.
   PubMed Web of Science ®Google Scholar
• SCARPIGNATO C, ZIMBARO G, VITULO F, BERTACCINI G: Caerulein delays gastric emtying of solids in man. Arch. Int. Pharmacodyn. Ther. (1981) 249:98–105.
   PubMedGoogle Scholar
• DOCKRAY GJ: Mediation and modulation of gastric afferent functions by regulatory peptides. In: Brain-Gut Interactions. Tache Y, Wingate D (Eds.), CRC Boston, MA (199 0:124–130.
   Google Scholar
• SCHWARTZ GJ, BERKOW G, MCHUGH PR, MORAN TH: Gastric branch vagatomy blocks nutrient and cholecystokinin-induced suppression o f gas tric emptying. Am. J. Physiol. Regd. Integr. Comp. Physiol. (1993) 264 (33):R630–R637.
   PubMed Web of Science ®Google Scholar
• KLEIBEUKER JH, BEEKHUIS H, JANSEN JBM, PEIRS DA, LAMERS CHBM: Cholecystokinin is a physiological hormonal mediator or fat-inhibitor of gastric emptying in man. Eur. I Clin. Invest (1988) 18:173–177.
   PubMed Web of Science ®Google Scholar
• LIDDLE RA, MORITA ET, CONRAD CK, WILLIAMS JA: Regulation of gastric emptying in humans by cholecystok-inin. j Clin. Invest. (1986) 77:992–996
   PubMed Web of Science ®Google Scholar
• LIDDLE RA, GOLDFINE ID, ROSEN MS, TAPLITZ RA, WIL-LIAMS JA: Cholecystokinin bioactivity in human plasma: molecular forms, responses to feeding, and relationship to gallbladder contractions. J. Clin. Invest. (1985) 75:1144–1152.
   PubMed Web of Science ®Google Scholar
• MEYER JH: Motility of the stomach and gastroduodenal junction. In: Physiology of the GI Tract. LR Johnson (Ed.) Raven, New York (1987):613–629.
   Google Scholar
• FRIED M, ERLACHER U, SCHWIZER W et al: Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Gastroen-terology (1991) 101:503–511.
   PubMed Web of Science ®Google Scholar
• MEYER BM, WERTH BA, BEGLINGER C et al.: Role of cholecystokinin in regulation of GI motor functions. Lancet (1989) 11:12-15. First important study on the physiological role of CCK in the control of GI motility using a CCKA antagonist.
   Google Scholar
• CHUA AS, BEKKERING M, ROVATI LC, KEELING PW: Clinical efficacy and prokinetic effect of the CCK-A antagonist loxiglumide in nonulcer dyspepsia. Ann. NY Acad. Sci. (1994) 713:451–453.
   PubMed Web of Science ®Google Scholar
• LI BASSI S, ROVATI LC, GIACOVELLI G, BOLONDI L, BARBARA L: Effects of loxiglumide, a cholecystokinin antagonist in non-ulcer dyspepsia. Gastroenterology (1990) 98:A77.
   Google Scholar
• BOROVICKA J, KREISS C, ASAL K et al.: Role of cholecystokinin as a regulator of solid and liquid emptying in humans. Am.j Physiol. (1996) 271(3):G448–G453.
   PubMed Web of Science ®Google Scholar
• SCHWIZER W, BOROVICKA J, KUNZ P et al.: Role of CCK in the regulation of liquid gastric emptying and gastric motility in humans. Gut (1996) 9.
   PubMed Web of Science ®Google Scholar
• CANTOR P, MORTENSEN PE, MYHRE J et al: The effect of the cholecystokinin receptor antagonist MK-329 on meal-stimulated pancreatobiliary output in humans. Gastroenterology (1992) 102: 1742-1751.
   Google Scholar
• KREISS C, SCHWIZER W, BOROVICKA J et al: Effect of SR 27897B, a new CCK-A receptor antagonist, on gastric emptying of a solid-liquid meal in humans. Gastroen-terology (1995) 108:A632.
   Web of Science ®Google Scholar
• CORAZZIARI E, RICCI R, BILIOTTI D et al Oral administration of CCK antagonist loxiglumide inhibits post-prandial gallbladder contraction without affecting gastric emptying. Dig. Dis. Sci. (1990) 35:50–54.
   PubMed Web of Science ®Google Scholar
• NIEDERAU C, MECKLENBECK W, HEINDGES T: Cholecystokinin does not delay galric emptying of regular meals in healthy humans. Hepatogastroenterology (1993) 40:380–383.
   PubMed Web of Science ®Google Scholar
• LIDDLE RA, GERTZ BJ, KANAYAMA S et al: Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. Clin. Invest. (1989) 84:1220-1225. Important study on the physiology of CCK.
   Google Scholar
• KATSCHINSKI M, DAHMEN G, REINSHAGEN M et al.: Cephalic stimulation of GI secretory and motor responses in humans. Gastroenterology (1992) 103:383–391.
   PubMed Web of Science ®Google Scholar
• KATSCHINSKI M, SCHIRRA J, BEGLINGER C et al.: Intestinal phase of human antro-pyloro-duodenal motility: cholinergic and CCK-mediated regulation. Eur. J. Clin. Invest. (1996) 26:574–583.
   PubMed Web of Science ®Google Scholar
• DE GIORGIO R, STAN GHELLINI V, RICCI-MACCARINI M et al.: Effects of dietary fat on postprandial GI motility are inhibited by a cholecystokinin type A receptor antagonist. Ann. NY Acad. SM. (1994) 703:226–231.
   Google Scholar
• MESQUITA MA, THOMPSON DG, AHLUWALIA NK et al.: Role of CCK in the regulation of dynamic and tonic mechanical response of the human gastric fundus to lipids. Cholecystokinin (1994) 713:393–394.
   Google Scholar
• MESQUITA MA, THOMPSON DG, TRONCON LEA, D'AMATO M, ROVATI LC: Effect of cholecystokinin-A receptor blockade on lipid induced gastric relaxation in man. Am. J. Physiol. (1997). (In Press.)
   Google Scholar
• FEINLE C, D'AMATO M, READ NW: Cholecystokinin-A receptors modulate gastric sensory and motor responses to gastric distension and duodenal lipid. Gas-troenterology (YEAR) 110:1379-1385. Important study showing the involvement of CCKA receptors in the modulation of GI sensations.
   Google Scholar
• SCHUBERT ML, SHAMBUREK RD: Control of acid secretion. Gastroenterol Clin. North. Am. (1990) 19:1–25.
   PubMed Web of Science ®Google Scholar
• SOLL AH: Gastric mucosal receptors. In: Handbook of Physiology, Section 6: The GI System. Schults SG, Makhlouf GM, Rauner BB (Eds.), American Physiological Society, Be-thesda MD (1989):193–214.
   Google Scholar
• SOLL A, ANIRIAN DA, PARK J, ELASHOFF JD, YAMADA T:
   Google Scholar
• •Cholecystokinin potently releases somatostatin from canine fimdic mucosal cells in short-term culture. Am. Physol (1985) 248:G569-573. Pioneering study on the role of CCK in gastric acid secretion.
   Google Scholar
• WANK SA, PISEGNA JR, DE WEERTH A: Brain and GI cholecystokinin receptor family: structure and functional expression. Proc. Natl. Acad. Sci. USA (1992) 89:8691–8695.
   PubMed Web of Science ®Google Scholar
• EVANS BE, RITTLE KE, BOCK ME et al.: Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonist. J. Med. Chem. (1988) 31:2235–2246.
   PubMed Web of Science ®Google Scholar
• BROOKS AM, GROSSMAN MI: Effect of secretion and cholecystokinin on pentagastrin-stimulated gastric acid secretion in man. Gastroenterology(1970) 59:114–119.
   PubMed Web of Science ®Google Scholar
• BROOKS AM, AGOSTI A, BERTACCINI G, GROSSMAN MI: Inhibition of gastric acid secretion in man by peptide analogues of cholecystokinin. New Engl. J. Med. (1970) 282:535–538.
   PubMed Web of Science ®Google Scholar
• CORAZZIARI E, SOLOMON TE, GROSSMAN MI: Effect of ninety-five percent pure cholecystokinin on gastrin-stimulated acid secretion in man and dog. Gastroenterol-ogy (1979) 77:91–95.
   PubMed Web of Science ®Google Scholar
• STENING GF, GROSSMAN MI: Gastrin-related peptides as stimulants of pancreatic and gastric secretion. Am. J. Physiol. (1969) 217:252–266.
   Google Scholar
• STENING GF, JOHNSON LR, GROSSMAN MI: The effect of cholecystokinin and caerulein on gastrin and histamine-evoked gastric secretion. Gastroenterology (1969) 57:44–50.
   PubMed Web of Science ®Google Scholar
• WORMSLEY KG: Gastric response to secretion and pancreozymin in man. Scand. J. Gasfroenterol (1968) 3:632–636.
   PubMed Web of Science ®Google Scholar
• KONTUREK SJ, KWIECIEN N, OBTULOWICZ W et al.: Cholecystokinin in the inhibition of gastric secretion and gastric emptying in humans. Digestion (1990) 45:1–8.
   PubMed Web of Science ®Google Scholar
• JENSEN RT, LEMP GF, GARDNER JD: Interaction of cholecystokinin with specific membrane receptors on pancreatic acinar cells. Proc. Natl. Acad. Sci. USA (1980) 77:2079–2083.
   PubMed Web of Science ®Google Scholar
• BURCKHARDT B, DELCO F, ENSINCK JW et al.:
   Google Scholar
• • Cholecystokinin is a physiological regulator of gastric acid secretion in man Eur. j Clin. Invest. (1994) 24:370-376. Detailed review on the role of CCK in gastric acid secretion.
   Google Scholar
• SNAPE WJ, MATERAZZO SA, COHEN S: Effect of eating and GI hormones on human colonic myloelectrical and motor activity. Gastroenterology (1978) 75:373–378.
   PubMed Web of Science ®Google Scholar
• FOSSATI-MARCHAL S, COFFIN B, FLOURIE. B etal: Effects of cholecystokinin octapeptide (CCK-OP) on the tonic and phasic motor activity of the human colon. Gastroen-terology (1994) 106(4):A499.
   Web of Science ®Google Scholar
• METER R, BEGLINGER C, THURMSHIRN M et al: Therapeutic effects of loxiglumide, a cholecystokinin antagonist, on chronic constipation in elderly patients, a prospective, randomised, double-blinded, controlled trial. J. Gasfroenterol (1993) 5:129–135.
   Google Scholar
• METER R, D'AMATO M, PULLWITT A etaL: Effect of a CCKA receptor antagonist in an experimental model of delayed colonic transit time in man. Gastroenterology (1994) 106(4):A538
   Web of Science ®Google Scholar
• METER R, BEGLINGER C, GIACOVELLI G, D'AMATO M: Effect of the CCK-Ar eceptor antagonist dexloxiglumide on postprandial gallbladder emptying and colonic transit time in healthy volunteers. Gastroenterology (1997) 112:A788.
   Web of Science ®Google Scholar
• WINGATE DL: Functional disorders of the small intestine. Sem. Gastrointest as. (1990) 1:37.
   Google Scholar
• KELLOW JE, PHILLIPHS SF: Altered small bowel motility in the irritable bowel syndrome is correlated with symptoms. Gastroenterology (1987) 92:1885–1893.
   PubMed Web of Science ®Google Scholar
• KELLOW JE, MILLAR LJ, PHILLIPS SF: Dysmotility of the small intestine is provoked by stimuli in the irritable bowel syndrome. Gut (1988) 29:1236–1243.
   PubMed Web of Science ®Google Scholar
• HARVEY RF, READ AE: Effect of cholecystokinin on colonic motility and symptoms in patients with the irritable bowel syndrome. The Lancet (1973) I:1 Pioneering study on the involvement of CCK in the pat hophysiology of a functional GI disorder.
   Google Scholar
• ROBERTS-THOMSON IC, FETTMAN MJ, JONSSON JR, FREWIN DB: Responses to cholecystokinin octapeptide in patients with functional abdominal pain syndromes. Gasfroenterol. Hepatol (1992) 7:293–297.
   PubMed Web of Science ®Google Scholar
• SJOLUND K, EKMAN R, LINDGREN S, REHFELD JF: Disturbed motilin and cholecystokinin release in the irritable bowel syndrome. Scand. J. Gasfrventerol. (1996) 31:1110–1114.
   PubMed Web of Science ®Google Scholar
• CANN PA, ROVATI LC, SMART H, SPILLER RC, WHORWELL PJ: Loxiglumide a CCK-A antagonist, in irritable bowel syndrome: a pilot multicenter clinical study. NY Acad. Sci. (1994) 713:449–450.
   PubMed Web of Science ®Google Scholar
• NIEDERAU C, FABER S, KARAUS M: Cholecystokinin's role in regulation of colon motility in health and in irritable bowel syndrome. Gastroenterology (1992) 102:1889–1898.
   PubMed Web of Science ®Google Scholar
• BARROW L, BLACKSHAW PE, WILSON CG, ROVATI L, SPILLER RC: Selective slowing of proximal colon transit in irritable bowel syndrome by the cholecystokinin-receptor antagonist, loxiglumide. Eur. j Gastroenterol Hepatol (1994) 6:381–387.
   Web of Science ®Google Scholar
• LIDDLE RA, GOLDFINE ID, WILLIAMS JA: Bioassays of plasma cholecystokinin in rats: effects of food, trypsin inhibitor, and alcohol. Gastroenterology (1984) 87:542–549.
   PubMed Web of Science ®Google Scholar
• LIDDLE RA, GOLDFINE ID, ROSEN MS, TAPLITZ RA, WIL-LIAMS JA: C hole cystokinin bioactivity in human plas ma: Molecular forms, responses to feeding, and relationship to gallbladder contractions. J. Clin. Invest (1985) 75:1144–1152.
   PubMed Web of Science ®Google Scholar
• KONTUREK JW, KONTUREK SJ, KUREK A et al: CCK receptor antagonism by loxiglumide and gall bladder contractions response to cholecystokinin, sham feeding and ordinary feeding in man. Gut (1989) 30:1136–1142.
   PubMed Web of Science ®Google Scholar
• MALESCI A, DEFAZIO C, FESTORAZZI S et aL: Effect of loxiglumide on gallbladder contractile response to cerulean and food in humans. Gastroenterology (1990) 98:1307–1310.
   PubMed Web of Science ®Google Scholar
• NIEDERAU C, HEINTGES T, ROVATI LC, STROHMEYER G: Effects of loxiglumide on gallbladder emptying in healthy volunteers. Gastroenterology (1989) 97:1331–1336.
   PubMed Web of Science ®Google Scholar
• MALESCI A, DEFAZIO C, FESTORAZZI S et al.: Dose-response effects of oral loxiglumide on postprandial gall-bladder emptying in man. Arz. neim-Forsch. (1992) 42:1359–1362.
   PubMed Web of Science ®Google Scholar
• BEGLINGER C, DILL S, MEYER B, WERTH B: Treatment of biliary colic with loxiglumide. Lancet (1989) 2:167.
   PubMed Web of Science ®Google Scholar
• NIEDERAU C, LeTHEN R, HEINTGES T: Effects of CCK on pancreatic function and morphology. Cholecystokinin (1994) 713:180–198.
   Google Scholar
• GARDNER JD, JENSEN RT: Secretagogue receptors on pancreatic acinar cells. In: Physiology of the GI Tract. Johnson LR (Ed.), Raven Press, New York (1987):1109–1126.
   Google Scholar
• JENSEN RT, LEMP GF, GARDNER JD: Interaction of cholecystokinin with specific membrane receptors on pancreatic acinar cells. Proc. Nati Acad. Sci. USA (1980) 77:2079–2083.
   PubMed Web of Science ®Google Scholar
• ADLER G, BEGLINGER C, BRAUN U eta].: Interaction of the cholinergic system and cholecystokinin in the regu-lation of endogenous and exogenous stimulation of pancreatic secretion in humans. Gastroenterology (1991) 100:537–543.
   Google Scholar
• BEGLINGER C, FRIED M, WHITEHOUSE I eta].: Pancreatic enzyme response to a liquid meal and to hormonal stimulation. J. Clin. Invest (1985) 75:1471–1476.
   Google Scholar
• KERSTENS PJSM, LANERS CBHW, JANSEN JBMJ eta].: Physi-ological plasma concentrations of cholecystokinin stimulate pancreatic enzyme secretion and gallbladder contraction in man. Life ScL (1985) 36:565–569.
   Google Scholar
• SCHMIDT WE, CREUTZFELDT W, SCHLESER A et al.: Role of CCK in regulation of pancreaticobiliary functions and gastrointestinal motility in humans: effects of loxiglumide. Am. J. Physiol. (1991) 260:G197–G206.
   PubMed Web of Science ®Google Scholar
• OWYANG C, LOUIE DS, TATUM D: Feedback regulation of pancreatic enzyme secretion-suppression of cholecystokinin release by trypsin. j Clin. Invest (1986) 77:2042–2047.
   PubMed Web of Science ®Google Scholar
• WALSH JH, LAMERS CB, VALENZUELA JE: Cholecystok-inin-octapeptide-like immunoreactivity in human plasma. Gastroenterology (1982) 82:438–444.
   PubMed Web of Science ®Google Scholar
• CANTOR P, MORTENSEN E, MYHRE J eta].: The effect of the cholecystokinin receptor antagonist MK-329 on meal-stimulated pancreaticobiliary output in humans. Gastroenterology (1992) 102:1242–1252.
   Google Scholar
• KATSCHINSKI M, DIPPEL C, REINSHAGEN M eta].: Induc-tion of the fed pattern of human exocrine pancreatic secretion by nutrients: role of cholecystokinin and neurotensin. Clin. Invest (1992) 70:902–908.
   Google Scholar
• BEGLINGER C, HILDEBRAND P, ADLER G et al.: Post-prandial control of gallbaldder contraction and exo-crine pancreatic secretion in man. Eur. J. Clin. Invest (1992) 22:827–834.
   PubMed Web of Science ®Google Scholar
• KONTUREK JW, GABRYELEWICZ A, KULESZA E, KON-TUREK SJ, DOMSCHKE W: Cholecystokinin (CCK) in the amino acid uptake and enzyme protein secretion by the pancreas in humans. Intj Pancreatol. (1995) 17(1):55–61.
   Web of Science ®Google Scholar
• ROVATI LC: Perspectives of CCK antagonists in pancre-atic research and clinical use. int. j Pancreatol. (1991) 8:215–226.
   PubMedGoogle Scholar
• LIDDLE RA, GERTZ BJ, KANAYAMA S eta].: Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystckinin receptor antagonist. J. Clin. Endocrinol Metab. (1990) 70:1312–1318.
   Google Scholar
• FRIED M, SCHWIZER W, BEGLINGER C eta].: Physiological role of cholecystokinin on postprandial insulin secre-tion and gastric meal emptying in man. Studies with the cholecystokinin receptor antagonist Loxiglumide. Dia-betologia (1991) 34:721–726.
   Google Scholar
• HILDEBRAND P, ENSINCK JW, KETTERER S eta].: Effect of cholecystokinin antagonist on meal-stimulated insulin and pancreatic polyp eptide release in humans. J. Clin. Endocrinol. Metab. (1991) 72:1123–1129.
   Google Scholar
• SCHMIDT WE, CREUTZFELDT W, HOCKER M et al Cholecystokinin in receptor antagonist loxiglumide modulates plasma levels of gastro-entero-pancreatic hormones in man. Feedback control of cholecystokinin and gastrin secretion. Eur. j Clin. Invest (1991) 21:501–511.
   Google Scholar
• BAUM F, NAUCK MA, EBERT R eta].: Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist. Digestion (1992) 53:189–199.
   Google Scholar
• AB RUZZESE JL, GHOLSON CF, DAUGHERTY K etal: A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. Pancreas (1992) 2:165–171.
   Web of Science ®Google Scholar
• MILITELLO C, SPERTI C, DI PRIMA F, PEDRAZZOLI S: Clinical evaluation and safety of loxiglumide (CCK-A receptor antagonist) in nonresectable pancreatic can-cer patients. Pancreas (1997) 14:222–228.
   PubMed Web of Science ®Google Scholar
• UPP JR, SINGH, P, TOWNSEND CM, THOMPSON JC: Pre-dicting response to endocrine therapy in human pan-creatic cancer with cholecystokinin receptors. Gastroenterol ogy (1987) 92:1677.
   Web of Science ®Google Scholar
• BELL RH, KUHLMAN ET, JENSEN RT, LONGNECKER DS: Overexpression of cholecystokinin receptors in azas er-ine-in neoplasms of the rat pancreas. Cancer Res. (1992) 52 (12):3295–3299.
   PubMed Web of Science ®Google Scholar
• WATSON SA, CROSBEE DM, MORRIS DL eta].: Therapeutic effect of the gastrin receptor antagonist, CR 2093 on GI tumour cell growth. Br. J. Cancer (1992) 65:879–883.
   Google Scholar
• CALAM J, GIBBONS A: Reply to letters to the editor entitled: CCK-A antagonists: which and how. Eur. j Clin. Invest (1995) 25:214.
   Google Scholar
• BERLIN RG, FRIEDINGER RM: Characterisation of MK-329. In: CCK Antagonists in Gastroenterology. Adler G, Beglinger C, (Eds.), Springer-Verlag, Berlin, Heidelberg (1990:70–79.
   Google Scholar
• SETNIKAR I, CHISTE R, MAKOVEC F, ROVATI LC, WAR-RINGTON SJ: Pharmacokinetics of loxiglumide after single intravenous or oral doses in man. Arzneim.-Forsch. (1988) 38:716–720.
   PubMed Web of Science ®Google Scholar
• SETNIKAR I, CHISTE R, GIACOVELLI G, ROVATI LC: Phar-macokinetics and tolerance of repeated oral doses of loxiglumide. Arzneimittelforschung (1989) 39:1454–1459.
   PubMed Web of Science ®Google Scholar
• JOHNSTON DE, KAPLAN MM: Pathogenesis and treat-ment of gallstones. New Engl. J. Med. (1993) 328:412-421. Comprehensive review on the mechanism of gallstone formation.
   Google Scholar
• WATANABE N, OTSUKI M: A cholecystokinin receptor antagonist, loxiglumide, stimulates biliary secretion in conscious rats. Eur. Pharmacol (1994) 264:331–336.
   PubMed Web of Science ®Google Scholar
• BHAT ST, POLLO DA, GARDNER JD: Identification of an irreversible cholecystokinin (CCK) receptor antago-nist. Gastroenterology (1992) 102:722.
   Google Scholar
• D'AMATO M, STAMFORD IF, BENNETT A: Studies of three non-peptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) inhuman isolated alimen-tary muscle and guinea-pig ileum. Br. J. Pharmacol (1991) 102:391–395.
   PubMed Web of Science ®Google Scholar
• MARCUS SN, HEATON KW: Intestinal transit, deoxy-cholic acid and the cholesterol saturation of bile: three inter-related factors. Gut (1986) 27:550–558.
   PubMed Web of Science ®Google Scholar
• HO KY, WEISSBERGER AJ, MARBACH P eta].: Therapeutic efficacy of the somatostatin analog SMS 201–995 (octreotide) in acromegaly. Ann. Intern. Med. (1990) 112:173–181.
   Google Scholar
• DOWLING RH, HUSSAINI SH, PURPHY GM, BESSER GM, WASS JAH: Gallstones during ocreotide therapy. Metabo-lism (1992) 41:22–33.
   PubMed Web of Science ®Google Scholar
• HUSSAINI SH, PEREIRA SP, VEYSEY MJ et al: Roles of gallbladder emptying and intestinal transit in the pathogenesis of octreotide induced gallbladder stones. Gut (1996) 38:775–783.
   PubMed Web of Science ®Google Scholar
• VEYSEY MJ, ARRATON SRD, MALLET A et al: Octreotide prolongs large bowel transit, thereby increasing the proportion of deoxycholic acid in bile and serum and the risk of gallstones. Gut (1996) 39:A9.
   PubMed Web of Science ®Google Scholar
• VEYSEY MJ ARRATON SRD, MALCOLM P et al.: Can cisapride overcome the effects of octreotide on intestinal transit, thereby reducing the propotion of deoxy-cholic acid inbile and serum, andthe risk of gallstones? Gut (1996) 39:A8.
   Google Scholar
• D'AMATO M, ROVATI LC: CCK-A antagonists: which and how. Eur. j Gin. Invest (1995) 25:213–214.
   PubMed Web of Science ®Google Scholar